Ocean DX
Molecular diagnostic kit that identifies sepsis-causing bacteria in blood within about 5 hours, for hospitals and clinicians
Highlights
- New on EvolcAdded 2026-11-11
About Ocean DX
Ocean DX develops a patented multiplexing molecular diagnostics kit for rapid sepsis diagnosis. The company says the test identifies 99% of sepsis-causing pathogens, including 1,200 Gram-positive and Gram-negative bacteria, with results in less than 5 hours.
The company describes itself as an in vitro diagnostic (IVD) company focused on infectious disease tests. Its stated target users are clinicians and intensive care teams treating suspected sepsis; its recent news references work on Oxford Nanopore sequencing for bacteremia detection.
Ocean DX was founded in 2019 and is headquartered in Pessac, France. Its team includes founders with backgrounds in molecular biology and biochemistry and clinical advisers from ICU departments in French hospitals.
Product: Patented multiplexing molecular diagnostics kit for rapid identification of sepsis-causing pathogens in blood.
Jobs at Ocean DX
Leadership
- Franck TARENDEAU · Founder – President – Chief Scientific OfficerSource: company website
- Cyril DIAN · Founder – Chief Technical OfficerSource: company website
More biotech & pharma companies
Oddifact
AI platform that prepares orphan drug programs for rare diseases and hands them to pharma partners for developmentYoung companyNew on EvolcOGD2 Pharma
Biotherapy developer targeting the tumour-restricted OAcGD2 antigen for high-risk neuroblastoma treatmentNew on EvolcOncodesign Services
Preclinical CRO running in vivo pharmacology, imaging and radiopharmaceutical studies for biotech and pharma sponsorsRemote-friendlyOne Biosciences
Single-cell tumour profiling from biopsy samples for oncologists and pharma and biotech drug developersNew on EvolcOrakl Oncology
Oncology drug discovery and clinical-response prediction for biopharma companies and research hospitalsYoung companyNew on EvolcOrganon France
Prescription medicines for women's health and general conditions, sold to clinicians and patients in more than 140 markets
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Analytics
- Google Analytics 4High confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Forms
- Google reCAPTCHAHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- ApacheHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Privacy & consent
- CookieYesHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.